Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CH.1.1.16NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CZ.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.1.18NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.29NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.47NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FK.1.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBC.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.26.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DS.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.1.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.27NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DV.6.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BN.1.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BN.1.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.11.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.14NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.1.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CQ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.4.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.17NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CC.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BZ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CK.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CM.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.50NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.60NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.52NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
W.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.250NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.63NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.27NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.23NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.130NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.44NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.315NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-16197.2US
B.1.1.204NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.50NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.170NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.232NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.84NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.76NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.301NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.269NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.5.4 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.323NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.15NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used